Robert W. O'Brien

Jun 19, 2024 | ajmc.com | Robert W. O'Brien |Diana I. Brixner |Ashley Peterson |Paul Jeffrey

OpinionVideoJune 19, 2024Author(s):In their closing remarks, the panel shares their view on the future of prescription digital therapeutics and the prospects for the widespread adoption and implementation of these therapeutics in health care systems. Video content above is prompted by the following questions:How can payers work with providers to establish protocols for appropriate PDT prescribing and monitoring efficacy?

Jun 12, 2024 | ajmc.com | Robert W. O'Brien |Diana I. Brixner |Ashley Peterson |Paul Jeffrey

OpinionVideoJune 12, 2024Author(s):Health care professionals discuss the optimal timeline for collaborating with provider advocates to develop and implement protocols that facilitate patient access to prescription digital therapeutics (PDTs). Video content above is prompted by the following questions:Dr. Brixner: At what point(s) in the product lifecycle do clinicians want/need to receive education from PDT manufacturers to effectively learn about, prescribe, and manage these digital therapies?

May 29, 2024 | ajmc.com | Robert W. O'Brien |Diana I. Brixner |Ashley Peterson |Paul Jeffrey

Dawn of the Age of Adopting PDTsPaul Jeffrey, PharmD, examines different contracting strategies that can help improve patient access to prescription digital therapeutics (PDTs).